Magic mushrooms for anxiety and depression

slimvictor

Bluelight Crew
Joined
Dec 29, 2008
Messages
6,477
Location
"Darkness cannot be dissipated with more darkness.
http://theweek.com/article/index/201851/Medicinal_magic_mushrooms_The_new_Prozac

Medicinal 'magic mushrooms': The new Prozac?
Why psychedelic drugs are returning as a legitimate treatment for depression
POSTED ON APRIL 14, 2010, AT 8:50 AM

Magic mushrooms: Just what the doctor ordered?

Marijuana isn't the only street drug doctors are using to treat ailing patients—a growing movement in the medical world is embracing hallucinogens as a treatment for depression. The drug psilocybin, a key ingredient in the recreational drug known as "magic mushrooms," and other mind-bending drugs fell out of favor with regulators in the 1960s, but doctors believe modern culture is ready to take another look at their medicinal value. Here, a quick guide to the 21st-century push for therapeutic psychedelics:

Which problems do psychoactive drugs treat?
Depression tops the list. But researchers have begun testing the drugs' effects on other mental problems, including obsessive-compulsive disorder, end-of-life anxiety, drug and alcohol addiction, and post-traumatic stress disorder in soldiers.

Is psilocybin the only hallucinogen under consideration for medical use?
No. While psilocybin has sparked the most interest, other drugs, like LSD and MDMA ("Ecstasy"), have also gained support in the medical world.

Why are these drugs getting a second chance?
A combination of increased acceptance of drug use in society and newly instituted, "rigorous protocols and safeguards," says John Tierney in The New York Times, have allowed scientists to reinvestigate the drugs' medicinal benefits. And so far, the results have been encouraging, with many test subjects reporting profound improvements in their mental states after only one use of psilocybin.

Who's conducting the studies?
A wide range of medical researchers and universities, like Johns Hopkins, the University of Arizona, Harvard, New York University, and the University of California, Los Angeles. Nonprofit groups, like the Heffter Research Institute and the Multidisciplinary Association for Psychedelic Studies (MAPS) are also supporting research into the drugs.

Is it safe to self-medicate with psychedelics?
Absolutely not. Aside from the highly illegal status of these drugs, psilocybin, LSD, and other psychedelics can have a wide range of effects, depending on the environment in which users consume them. Because of this, researchers tightly control their test subjects' environments while administering the drugs, and aid them through periods of anxiety sometimes brought on by their use.
 
i wouldnt say its unsafe to self medicate, but of course, dont self medicate too much, in case you get ill, fall down, hit your head-

OR

dont self medicate, then decide to watch The Ring.

;)



+1 for doctors bringin back the trippyness =D
 
Yeah! These chemicals allow you to reflect on life from a different perspective! They can be life changing tools.

For me Mescaline would be a winner! It's very gentle and it feels as though your looking through the eye's of a child.

Mescaline has been the most warm and wonderous experience. Like massive breath of fresh air each time.
 
Last edited:
Hallucinogen May Reduce Cancer Anxiety

http://www.medscape.com/viewarticle/728185?src=mp&spon=30&uac=137653CN

No "Bad Trips"; More Studies on the Way

Nick Mulcahy

Authors and Disclosures - Journalist
Nick Mulcahy

Nick Mulcahy is a senior journalist for Medscape Hematology-Oncology. Before joining Medscape, Nick was a freelance medical news writer for 15 years, working for companies such as the International Medical News Group, MedPage Today, HealthDay, McMahon Publishing, and Advanstar. He is also the former managing editor of breastcancer.org. He can be contacted at [email protected].

September 8, 2010 — Psilocybin, a hallucinogen that occurs naturally in "magic mushrooms," appears to be a safe and possibly effective treatment for anxiety in patients with advanced-stage cancer, say California researchers.

A 12-patient pilot study conducted at the Harbor-UCLA Medical Center in Torrance, California, showed that a single experience with the drug was associated with a significant reduction in anxiety at 1 and 3 months after treatment and improvement of mood that reached significance at 6 months.

The study is the first research on psilocybin for cancer-related anxiety in more than 35 years.

A variety of hallucinogens were the subject of studies from the 1950s to the early 1970s in cancer patients suffering from anxiety and despair, say the authors of the pilot study, led by Charles S. Grob, MD, professor of psychiatry at the UCLA David Geffen School of Medicine.

Despite "promising results," these previous studies were never followed up with more research, write Dr. Grob and colleagues in a paper published online September 6 in the Archives of General Psychiatry.

The compound was stigmatized from what occurred in the 1960s.

"The compound was stigmatized from what occurred in the 1960s," explained Roland Griffiths, MD, professor of behavioral biology at Johns Hopkins School of Medicine in Baltimore, Maryland.

Dr. Griffiths was not involved in the study and was asked for comment by Medscape Medical News.

He is leading another larger trial of psilocybin at Johns Hopkins for the treatment of anxiety in cancer patients who are at a variety of stages — not just advanced disease. There is a similar study being conducted at New York University. Both of these studies are now enrolling cancer patients.

"Anxiety in cancer patients can be enormously difficult to treat," said Dr. Griffiths. "These patients are facing core questions such as 'What is the meaning of life?' and 'Is there life after death?'. Xanax is not going to take care of that."

No Severe Anxiety Induced

The new study was a double-blind placebo-controlled study of a "moderate dose" (0.2 mg/kg) of psilocybin, in which subjects acted as their own control. The placebo was niacin, which was chosen because it often induces a mild physiological reaction, such as flushing, but no psychological alterations, explain the authors.

The 12 subjects had durations of cancer that ranged from 2 months to 18 years. All were in advanced stages of disease at the time of the study and suffering from anxiety.

Eight of the subjects had previous hallucinogen experience; in 4 cases, it was more than 30 years ago. The hallucinogens that were previously taken included lysergic acid diethylamide (LSD; 7 subjects), hallucinogenic mushrooms (5 subjects), peyote (2 subjects), and ayahuasca (2 subjects).

The subjects were informed about the range of potential emotional reactions to the drug, including "challenging psychological issues."

The study design called for participants to stay in a hospital clinical research room for a 6-hour session after ingesting either drug or placebo and then to return for another session weeks later. Thus, there were 2 sessions in total: 1 with the drug and 1 with placebo.

The room was decorated with flowers and fabric wall hangings to "provide a pleasing and comfortable environment," write the authors. A cardiac monitor was attached to the participants for 24 hours. Staff briefly checked in with study subjects every hour.

The overall scenario was relaxed, suggest the authors.

"The subject was encouraged to lie in bed wearing eye shades during the first few hours, as well as to put on headphones to listen to preselected music," they write.

The investigators found that the moderate dose of psilocybin produced no clinically significant adverse events, including cardiac events.

"All subjects tolerated the treatment sessions well, with no indication of severe anxiety or a 'bad trip'," write the authors.

Psychological testing was undertaken before and after the sessions, for up to 6 months. All 12 of the subjects completed at least 3 months of follow-up; however, 2 died and 2 became seriously ill during follow-up.

The State–Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 month (P = .001) and 3 months (P = .03) after treatment. Also, a "substantial but nonsignificant decrease" was evident for the state anxiety subscale 6 hours after psilocybin administration; this was not observed after placebo, write the authors.

The Beck Depression Inventory showed an improvement in mood that reached significance at 6 months. The authors note that the scores dropped — which indicates a positive response — early on, but only reached statistical significance at the end of the testing.

The Profile of Mood States test identified mood improvement after treatment with psilocybin "that approached but did not reach significance," said the authors.

Study Subjects Critical of Placebo

It was "almost always apparent" to study participants and staff which compound had been taken. A "consistent subject critique of the study was that the placebo sessions were perceived as far less worthwhile than those with psilocybin," report the Dr. Grob and his authors.

"Many of the subjects suggested that future protocols provide the opportunity for a second psilocybin session several weeks after the first," the authors add, explaining that the study subjects felt that a follow-up experience would "reinforce and extend the perceived therapeutic effects of the initial session."

Dr. Griffiths' ongoing study at Johns Hopkins provides just that. In a second session, participants will receive a higher dose of psilocybin.

According to the study authors, a higher dose might be more effective because previous researchers "reported more pronounced therapeutic effects with a higher-dose model."

Most of the volunteers self-referred.

Either way, conducting clinical trials of psilocybin is not easy, explained Dr. Griffiths, because of the difficulty in getting patients referred from oncologists.

"Recruitment has been slow," said Dr. Griffiths. "Most of the volunteers self-referred." He encouraged interested parties to visit the study Web site for more information.

The authors have disclosed no relevant financial relationships.

Arch Gen Psychiatry. 2010. Published online September 6, 2010. Abstract
 
Either way, conducting clinical trials of psilocybin is not easy, explained Dr. Griffiths, because of the difficulty in getting patients referred from oncologists.

"Recruitment has been slow," said Dr. Griffiths. "Most of the volunteers self-referred." He encouraged interested parties to visit the study Web site for more information.

Scientists are not good salespeople. It takes a very nuanced set of skills to be able to talk medical specialists into referring patients. One has to have an Olympic ability to lick asses, and has to be able to chew and swallow fecal matter without grimacing.

Thank you leftwing for posting this.
 
Mushrooms may help ease anxiety

Found this after reading a Reuters released version in a newspaper.

URL: http://archpsyc.ama-assn.org/cgi/content/short/archgenpsychiatry.2010.116

Pilot Study of Psilocybin Treatment for Anxiety in Patients With Advanced-Stage Cancer
Charles S. Grob, MD; Alicia L. Danforth, MA; Gurpreet S. Chopra, MD; Marycie Hagerty, RN, BSN, MA; Charles R. McKay, MD; Adam L. Halberstadt, PhD; George R. Greer, MD
Arch Gen Psychiatry. Published online September 6, 2010. doi:10.1001/archgenpsychiatry.2010.116

Context Researchers conducted extensive investigations of hallucinogens in the 1950s and 1960s. By the early 1970s, however, political and cultural pressures forced the cessation of all projects. This investigation reexamines a potentially promising clinical application of hallucinogens in the treatment of anxiety reactive to advanced-stage cancer.

Objective To explore the safety and efficacy of psilocybin in patients with advanced-stage cancer and reactive anxiety.

Design A double-blind, placebo-controlled study of patients with advanced-stage cancer and anxiety, with subjects acting as their own control, using a moderate dose (0.2 mg/kg) of psilocybin.

Setting A clinical research unit within a large public sector academic medical center.

Participants Twelve adults with advanced-stage cancer and anxiety.

Main Outcome Measures In addition to monitoring safety and subjective experience before and during experimental treatment sessions, follow-up data including results from the Beck Depression Inventory, Profile of Mood States, and State-Trait Anxiety Inventory were collected unblinded for 6 months after treatment.

Results Safe physiological and psychological responses were documented during treatment sessions. There were no clinically significant adverse events with psilocybin. The State-Trait Anxiety Inventory trait anxiety subscale demonstrated a significant reduction in anxiety at 1 and 3 months after treatment. The Beck Depression Inventory revealed an improvement of mood that reached significance at 6 months; the Profile of Mood States identified mood improvement after treatment with psilocybin that approached but did not reach significance.

Conclusions This study established the feasibility and safety of administering moderate doses of psilocybin to patients with advanced-stage cancer and anxiety. Some of the data revealed a positive trend toward improved mood and anxiety. These results support the need for more research in this long-neglected field.

Trial Registration clinicaltrials.gov Identifier: NCT00302744

Author Affiliations: Departments of Psychiatry (Drs Grob and Chopra) and Internal Medicine (Dr McKay), Harbor-UCLA Medical Center and Los Angeles Biomedical Research Institute, Torrance (Drs Grob and McKay and Mss Danforth and Hagerty) and Department of Psychiatry, University of California, San Diego, La Jolla (Dr Halberstadt); and Heffter Research Institute, Santa Fe, New Mexico (Dr Greer).
 
I often find Psilocybin Mushrooms helpful with my Depression / Anxiety.
It's almost as though they partially reset my emotions for a temporary timeframe afterwards.
I was feeling really, really bad a few weeks ago (almost the worst I've been before) and after a small trip I found that I felt much clearer, less Depressed and less Anxious.

And the feeling of laughing out loud for no reason what-so-ever was utterly amazing.. :)
 
I often find Psilocybin Mushrooms helpful with my Depression / Anxiety.
It's almost as though they partially reset my emotions for a temporary timeframe afterwards.
I was feeling really, really bad a few weeks ago (almost the worst I've been before) and after a small trip I found that I felt much clearer, less Depressed and less Anxious.

And the feeling of laughing out loud for no reason what-so-ever was utterly amazing.. :)
when i first saw this thread i thought i was going to read it and reply something along the lines of " tripping when your already feeling anxious is only going to exacerbate the problem" but im actually fully in agreeance with what you are saying %)
 
^ I have the feeling I'd only have the balls to trip during end-stage cancer if I was completely naive and never tripped before. Especially on mushrooms of all things. I am completely healthy and things are going better for me than most people but I still feel like a trainwreck for at least the first half of the trip. Like fetal position, rocking back and forth in a dark corner of my room. Shit was different when I was 16...

If I get terminal cancer I'll be on a steady diet of mdma, oxyxodone, and diazepam thank you very much.
 
when i first saw this thread i thought i was going to read it and reply something along the lines of " tripping when your already feeling anxious is only going to exacerbate the problem" but im actually fully in agreeance with what you are saying %)

I think it could go both ways to be honest.
More recently I've found myself more able to totally block out any of the old "Fuck! Trip incoming - range 20mins!" feelings, if that makes any sense =D
I feel more in control. Though I'd imagine that that feeling could be totally ripped apart by taking an ego-death-dose.

One thing to consider though is that when you've had part of a trip that's really intense and could be thought of as "bad", when you come out of that place you almost feel as though now you've experienced the worst and that nothing else could touch you in such a negative way :)
It does add strength - emotional, charactorial (not a word but it fuckin should be! =D) etc. :)

I am completely healthy and things are going better for me than most people but I still feel like a trainwreck for at least the first half of the trip. Like fetal position, rocking back and forth in a dark corner of my room. Shit was different when I was 16...

If I get terminal cancer I'll be on a steady diet of mdma, oxyxodone, and diazepam thank you very much.

What is it that you find sends you to that place mate? Ha! Yes! When I took my first dose I think I was ~15 or so and, regardless of what happened, I was totally fine - Nothing could go wrong (except the laws of Physics: you could touch anything and make it melt ;) ).

And yep, give me shit loads of MDMA, Diamorphine and Nimetazepam when I'm about to go... Jeeeeebus I can only imagine how lush that would be...
**Dribbles**
 
imagine tripping when your are in advanced stage cancer


talk about a bad fucking trip

"dude i think im dying...I AM DYING" *sadface sadface

I don't know...I can't even imagine how I would feel if I were told today that I only have a month to live. I would be devastated on on many levels and most of us would. I'm sure two weeks down the line I will be so worn out by crying and hysteria that I would probably feel numb. Now...if I were in the right environment during this "Numb" period and I ingested some psilocybin mushrooms, I would probably come to an understanding about what is going on and why this is a natural part of life, etc. I'm sure I would cry but I can see them benefiting someone who is about to die and come to peace with that.
 
imagine tripping when your are in advanced stage cancer


talk about a bad fucking trip

"dude i think im dying...I AM DYING" *sadface sadface

No, dude, that's what being SOBER is like when you have advanced stage cancer. Tripping on psilocybin after the realization has set in can help someone come to terms with the facts of their impending death and they can be much better off afterwards.
 
I imagine that I would definitely be interested in using psychedelics to come to terms with death, and to make sense of my life, if I were dying.

I am not sure that I would want to go out while tripping on LSD, like Huxley, but using psychedelics to help the larger process seems like it would be extremely useful.

And mushrooms tend to be very spiritual for me, so I would probably choose them over LSD, come to think of it. Ayahuasca could also be very useful, but the physical distress associated with taking it might make mushrooms a better choice.

(When I saw the title, I thought of the anxiety I always feel when coming up on mushrooms!)
 
Magic mushrooms may ease anxiety of cancer

By Julie Steenhuysen
Reuters
updated 9/7/2010 4:08:21 PM ET 2010-09-07T20:08:21


CHICAGO — The hallucinogen psilocybin — known by the street name magic mushrooms — may help ease the anxiety that often accompanies late-stage cancer, U.S. researchers said on Monday.

Cancer patients given a moderate dose of psilocybin — a hallucinogen with effects similar to LSD — were measurably less depressed six months after a single dose compared with a placebo. Patients seemed somewhat less anxious, they reported in the Archives of General Psychiatry.

The pilot study of 12 cancer patients was designed to prove that hallucinogenic drugs could be studied safely as a way to relieve the distress of advanced cancer.

It revives a promising field of study lasting from the 1950s to the early 1970s that suggested some patients experienced powerful and sustained improvement in mood and anxiety from hallucinogens.

Researchers said the studies were abandoned in the early 1970s when hallucinogenic drugs such as LSD — lysergic acid diethylamide — became widely used on the streets, leading to strict federal laws regulating their use.

"Forty to 45 years ago, the culture was going through tremendous upheaval. These compounds were associated with a very politically active counterculture," said Dr. Charles Grob of Harbor-University of California Los Angeles Medical Center and the Los Angeles Biomedical Research Institute.

"It was something of a public health crisis. Everything had to be shut down," Grob said in a telephone interview.

Federal law prohibits the use of the magic mushroom compound for any purpose. If it proves effective among late-stage cancer patients, U.S. regulators would need to make special accommodation for its use, Grob said.

Grob's study looked to see whether psilocybin could help ease some of the anxiety of dying cancer patients.

During the treatment phase of the study, patients were given a moderate dose of psilocybin and watched closely for six hours. They were told to lie still with their eyes closed as they wore headphones and listened to soothing music.

During the placebo phase, each of the 12 patients received a dose of niacin — a vitamin that raises levels of good cholesterol — and given the same instructions.

The treatments were given in random order and neither the doctors nor the patients were told which compound was administered.

All the volunteers tolerated the treatment sessions well, with no signs of severe anxiety or a "bad trip." Most patients showed a trend of improvement in their symptoms of anxiety and at six months, and there was a statistically significant improvement on one depression scale.

Grob said the pilot study proved the drug could be studied safely in cancer patients. He said two other academic research institutions in the United States — Johns Hopkins University in Baltimore and New York University -- were doing similar studies using a slightly higher dose.

"Times have changed and it's now possible to pick up this research model again," he said.

continued at http://www.msnbc.msn.com/id/39028828/ns/health-cancer
 
Top